A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease - I9X-MC-MTAE

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210449

Enrollment

330

Registered

2021-11-24

Start date

2021-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Interventions

-Drug: LY3372689 given orally -Drug: Placebo given orally -Experimental: LY3372689 High Dose LY3372689 given orally Intervention: Drug: LY3372689 -Experimental: LY3372689 Low Dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Gradual and progressive change in memory function reported by participants or informants for >= 6 months -MMSE score of 22 to 30 (inclusive) at baseline -CDR global score of 0.5 to 1.0 (inclusive), with a memory box score >=0.5. -Meet 18F flortaucipir positron emission tomography (PET) scan (central analysis) criteria -Have a study partner who will provide written informed consent to participate

Exclusion criteria

Exclusion criteria: -Contraindication to MRI or PET scans -Have known allergies to LY3372689, related compounds, or any components of the formulations

Design outcomes

Primary

Measure	Time frame
Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS) [ Time Frame: Baseline, 76 to 124 Weeks ] Change from Baseline to End Time Point in iADRS will be measured in participants with early symptomatic Alzheimer's Disease (AD) with demonstrated presence of moderate levels of tau pathology	—

Countries

Australia, Canada, Japan, Netherlands, Poland, United States

Contacts

Public ContactTrial Guide Call Center

Eli Lilly Japan K.K.

LTG_CallCenter@lists.lilly.com+81-120-023-812

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026